Pulmonary Drug Delivery Systems: Technologies and Global Markets

November 22, 2011

Wellesley, Mass. – In a recent release, PULMONARY DRUG DELIVERY SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS (HLC094A) from BCC Research (www.bccresearch.com), the global market for pulmonary drug delivery systems totaled $22.5 billion for 2011. That number is projected to increase at a compound annual growth rate (CAGR) of 14.3% between 2011 and 2016, reaching nearly $44 billion in 2016.

The global market for pulmonary drug delivery technologies can be broken down into three segments – metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, which are sometimes referred to as soft mist inhalers.

The MDI segment totaled nearly $14.4 billion in 2011 and is expected to increase at a CAGR of 15.7% to reach nearly $29.8 billion in 2016.

The DPI segment, worth $7.5 billion in 2011, should be worth nearly $13.4 billion in 2016, a CAGR of 12.3%.

The segment made up of nebulizers was valued at $622 million in 2011 and, after increasing at a 5% CAGR, should be worth $795 million in 2016.

Pulmonary drug delivery has emerged as a more relevant alternative for delivering drugs. Respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema are therapeutic areas of the pulmonary sector. Recent technological advancements, however, have used pulmonary devices for the treatment of nonrespiratory conditions such as diabetes and migraines. 

Advancements in formulating technology are expected to push sales of dry powder inhalers, replacing metered-dose inhalers to a large extent. There is a need to understand the trends in this market, currently available devices and their problems, and the latest developments for drug delivery to the lungs.

Primary drivers of global growth in the market are the rising incidence of respiratory disorders, the growing prevalence of asthma and chronic obstructive pulmonary disease (COPD), and the increasing importance of drug self-administration for chronic conditions. Dynamic innovations in pharmaceutical formulations and combinations, the emergence of sophisticated inhaler device designs, and consumer desire for alternatives to invasive methods are other key factors in the growth of this industry.

This report will be of particular interest to pharmaceutical, chemical, and biotechnology companies, as well as to hospitals, doctors, and those in related fields. The report also will be of high interest to professionals within governments and regulatory agencies to understand the scope and pace of these pulmonary technologies as they reach the market.

To Contact us, click here  

Pulmonary Drug Delivery Systems: Technologies and Global Markets( HLC094A )
Publish Date: Jan 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.